These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9816174)

  • 1. Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration.
    Lindnér P; Heath D; Howell S; Naredi P; Hafström L
    Clin Cancer Res; 1996 Feb; 2(2):311-7. PubMed ID: 9816174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional lymphatic drug exposure following intraperitoneal administration of 5-fluorouracil, carboplatin, and etoposide.
    Lindnér P; Heath DD; Shalinsky DR; Howell SB; Naredi P; Hafström L
    Surg Oncol; 1993; 2(2):105-12. PubMed ID: 8252198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of carcinomatosis and intraperitoneal 5-fluorouracil on peritoneal blood flow modulated by vasopressin in the rat as measured with the 133Xe-clearance technique.
    Oman M; Tölli J; Naredi P; Hafström LO
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):213-8. PubMed ID: 15138707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model.
    Pestieau SR; Stuart OA; Sugarbaker PH
    Eur J Surg Oncol; 2000 Nov; 26(7):696-700. PubMed ID: 11078617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I pharmacokinetic study of intraperitoneal etoposide.
    O'Dwyer PJ; LaCreta FP; Daugherty JP; Hogan M; Rosenblum NG; O'Dwyer JL; Comis RL
    Cancer Res; 1991 Apr; 51(8):2041-6. PubMed ID: 2009523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.
    Los G; Smals OA; van Vugt MJ; van der Vlist M; den Engelse L; McVie JG; Pinedo HM
    Cancer Res; 1992 Mar; 52(5):1252-8. PubMed ID: 1737387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preoperative intraperitoneal versus intravenous carboplatin chemotherapy for advanced gastric cancer, pharmacokinetics and drug accumulation study].
    Wang J; Chen J; Ma S
    Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):300-2. PubMed ID: 11038765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model.
    Glehen O; Stuart OA; Mohamed F; Sugarbaker PH
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):79-84. PubMed ID: 15048586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
    Mohamed F; Marchettini P; Stuart OA; Sugarbaker PH
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):405-10. PubMed ID: 12879282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological bases of intraperitoneal chemotherapy].
    Gladieff L; Chatelut E; Dalenc F; Ferron G
    Bull Cancer; 2009 Dec; 96(12):1235-42. PubMed ID: 19923051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model.
    Marchettini P; Stuart OA; Mohamed F; Yoo D; Sugarbaker PH
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):499-503. PubMed ID: 12107555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study.
    Miyagi Y; Fujiwara K; Kigawa J; Itamochi H; Nagao S; Aotani E; Terakawa N; Kohno I;
    Gynecol Oncol; 2005 Dec; 99(3):591-6. PubMed ID: 16095677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer.
    Oman M; Lundqvist S; Gustavsson B; Hafström LO; Naredi P
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):603-9. PubMed ID: 16047145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide.
    McClay EF; Goel R; Andrews P; Gorelick S; Kirmani S; Kim S; Braly P; Plaxe S; Hoff S; Alcaraz J
    Br J Cancer; 1993 Oct; 68(4):783-8. PubMed ID: 8398708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics.
    de Lima Vazquez V; Stuart OA; Mohamed F; Sugarbaker PH
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):108-12. PubMed ID: 12759776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of peritoneal carcinomatosis using carboplatin-loaded hydroxyapatite particles.
    Takeyama H; Mohri N; Mizuno I; Akamo Y; Sawai H; Manabe T; Yotsuyanagi T; Nakamura S
    Anticancer Res; 2006; 26(6B):4603-6. PubMed ID: 17201184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.
    Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Duffaud F; Digue L; Tranchand B; Monjanel-Mouterde S; Guillet P; Nicoara A; Baciuchka M; Bagarry-Liegey D; Lacarelle B; Noble A; Durand A; Favre R
    Ther Drug Monit; 2006 Apr; 28(2):212-8. PubMed ID: 16628133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intraperitoneal and intrathoracic administration of hydroxyapatite-carboplatin (HAp-CBDCA)].
    Mohri N; Mizuno I; Akamo Y; Takeyama H; Manabe T
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1791-3. PubMed ID: 10560396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration.
    Hande K; Messenger M; Wagner J; Krozely M; Kaul S
    Clin Cancer Res; 1999 Oct; 5(10):2742-7. PubMed ID: 10537337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.